(SeaPRwire) –   TAIPEI, May 21, 2026 — Formosa Pharmaceuticals, Inc. has announced the selection of its abstract for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29 to June 2, 2026, in Chicago, Illinois. The abstract details the distinct binding profile and preclinical effectiveness of TSY-310, an innovative bispecific antibody-drug conjugate (ADC).  TSY-310 is designed to target both EGFR and ROR1 concurrently, two receptors often found together in common solid tumors. Its unique bispecific design improves target binding and delivery into cells, promoting a strong bystander effect to overcome tumor heterogeneity.

Details

• Title: TSY-310, A Novel Bispecific EGFR x ROR1 ADC, Exhibits Potent Antitumor Activity in Heterogeneous Breast Tumors Through Enhanced Internalization and Bystander Cytotoxicity
• Session: Developmental Therapeutics: Molecularly Targeted Agents and Tumor Biology
• Date & Time: May 30, 2026, 1:30 pm – 4:30 pm CT
• Abstract Number: 3086
• Poster Number: 223
• Presenter: Dr. Kuo-Ming Yu, Ph.D., Director, CMC and Production

Highlights

• Superior Selectivity: Bispecific binding increases internalization specifically in tumor cells that express both EGFR and ROR1.
• Enhanced Payload Delivery: Demonstrates efficient movement to lysosomes and the subsequent release of the cytotoxic drug.
• Bystander Efficacy: Destroys nearby tumor cells lacking the target antigens, which is crucial for treating complex, mixed tumor populations.

“Being selected for ASCO recognizes the potential of this program to meaningfully contribute to the future of oncology care,” stated Erick Co, President & CEO of Formosa Pharmaceuticals. “We look forward to making TSY-310 available as a tool for oncologists and patients confronting the limitations of conventional single-target treatments.”

The complete abstract and presentation information will be accessible on the ASCO and company websites, following the conference guidelines.

About TSY-310: TSY-310 is a next-generation bispecific ADC directed against EGFR and ROR1. Utilizing an efficient, streamlined protein structure for high-affinity target binding, TSY-310 is intended to offer a long-lasting, “best-in-class” treatment for patients with advanced solid tumors, such as Non-Small Cell Lung Cancer (NSCLC).

About Formosa Pharmaceuticals, Inc.: Formosa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on creating significant therapies in ophthalmology and oncology. Its first approved product, a novel corticosteroid formulation cleared by the US FDA (BYQLOVI) and Health Canada (CLOBIVIS), provides fast and sustained relief from inflammation and pain for patients healing from eye surgery. More information is available at www.formosapharma.com.

SOURCE Formosa Pharmaceuticals Inc.,